Preview

Медицинский алфавит

Расширенный поиск

Ожирение и синдром раздраженного кишечника. Есть ли связь?

https://doi.org/10.33667/2078-5631-2019-2-13(388)-14-19

Полный текст:

Аннотация

В обзорной статье изучаются механизмы коморбидностисиндрома раздраженного кишечника и ожирения. Особое внимание уделяется генетическим, гормональным механизмам коморбидности, роли расстройств тревожного и депрессивного спектра, влиянию микробиоты. Изучение механизмов коморбидности может быть целесообразным в плане более детального изучения патофизиологии и оптимизации терапии СРК и ожирения.

Об авторах

В. И. Симаненков
Кафедра терапии и клинической фармакологии ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России
Россия

д.м.н., проф.

г. Санкт-Петербург



С. В. Тихонов
Кафедра терапии и клинической фармакологии ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России
Россия

к.м.н. доцент кафедры

г. Санкт-Петербург



В. Д. Декканова
Кафедра терапии и клинической фармакологии ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России
Россия

клинический ординатор

г. Санкт-Петербург



Список литературы

1. Морбидное ожирение под редакцией академика РАН И. И. Дедова, 2014, ISBN: 978–5–9986–0171–2, 608 стр. МИА.

2. The Lancet. Trends in adult body-mass index in 200 countries from 1975 to 2014 Apr 2; 387 (10026): 1377–1396. DOI: 10.1016/S 0140–6736(16)30054-X.

3. Recent developments in the pathophysiology of irritable bowel syndrome, World J Gastroenterol 2015 Jul 7; 21 (25): 7621–36. DOI: 10.3748/wjg.v21.i25.7621.

4. WGO Global Guidelines IBS.

5. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome — etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667–672. doi: 10.1038/sj.ejcn.1602367.

6. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion2001; 63: 108–115. doi.org/10.1159/000051878.

7. Riadh Sadik, Einar Bjornsson, Magnus Simren. The relationship between symptoms, body mass index, gastrointestinal transit and stoolfrequency in patients with irritable bowel syndrome. European Journal of Gastroenterology & Hepatology. 22 (1): 102–108, JAN 2010. DOI: 10.1097/MEG.0b013e32832ffd9b.

8. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil. 2004 Aug; 16 (4): 413–9. DOI.org/10.1111/j.1365–2982.2004.00530.x

9. Cremonini F, Camilleri M, Clark MM, Beebe TJ, Locke GR, Zinsmeister AR, Herrick LM, Talley NJ. Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. Int J Obes (Lond) 2009; 33: 342–353. DOI: 10.1038/ijo.2008.272.

10. Ostgaard H, Hausken T, Gundersen D, El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep 2012; 5: 1382–1390. DOI: 10.3892/mmr.2012.843.

11. Kubo M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T. Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. Neurogastroenterol Motil 2011; 23: 249–254. doi: 10.1111/j.1365–2982.2010.01640.x.

12. Oganov R. G. Simanenkov V. I. Bakulina N. A. Comorbidities in practice. Clinicalguidelines.

13. Montalescot G, Sechtem U, Achenbach S, еt al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct; 34 (38): 2949–3003. DOI:10.1093/eurheartj/eht296.

14. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986; 27: 37–40. DOI: PMC 1433171.

15. Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol. 2000; 95: 451–456. DOI: 10.1111/j.1572–0241.2000.01766.x.

16. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. 2009; 403: 47–55. DOI: 10,1016/j.cca.2009.01.028.

17. Ahonen A, Kyösola K, Penttilä O. Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon. Ann Clin Res. 1976; 8: 1–7. DOI: 10.3748/wjg.v19.i23.3602.

18. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998; 42: 42–46. PMID: 9505884.

19. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005; 3: 349–357. DOI: 10,1016/j.cgh.2006.04.017.

20. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA.Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006; 130: 34–43. DOI: 10.1053/j.gastro.2005.09.031.

21. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA. 1993; 90: 2542–2546. doi.org/10.1073/pnas.90.6.2542.

22. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274: 1527–1531. DOI: 10.1126/science.274.5292.1527.

23. Eisenstein SA, Bischoff AN, Gredysa DM, Antenor-Dorsey JA, Koller JM, Al-Lozi A, et al. Emotional Eating Phenotype is Associated with Central Dopamine D 2 Receptor Binding Independent of Body Mass Index. Sci Rep. 2015; 5: 11283.

24. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet. 2001; 357: 354–7.

25. Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, et al. Association of central serotonin transporter availability and body mass index in healthy Europeans. EurNeuropsychopharmacol. 2014; 24: 1240–7.

26. .Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. 2009; 403: 47–55. [PubMed]).

27. Koskela AK, Kaurijoki S, Pietilainen KH, Karhunen L, Pesonen U, Kuikka JT, et al. Serotonin transporter binding and acquired obesity — an imaging study of monozygotic twin pairs. Physiol Behav. 2008; 93: 724–32.

28. Смулевич А. Б. Сыркин А. Л. Психокардиология 2005; SBN-13 (EAN): 9785894813356, 784 стр., МИА.

29. 29.World Health Organization. Global health estimates 2014 summary tables: YLD by cause, age, and sex, 2000–2012. Published June 2014.

30. Goldstein JM, Holsen L, Huang G, Hammond BD, James-Todd T, Cherkerzian S, Hale TM, Handa RJ. Prenatal stress-immune programming of sex differences in comorbidity of depression and obesity / metabolic syndrome. Dialogues Clin Neurosci. 2016 Dec; 18 (4): 425–436.

31. Vicennati V., Ceroni L., Genghini S., Patton L., Pagotto U., Pasquali R. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring). 2006; 14 (2):235–243 [PubMed].

32. Bujalska IJ., Kumar S., Hewison M., Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology.1999; 140 (7): 3188–3196.

33. Goldstein JM., Handa RJ., Tobet SA. Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease. Front Neuroendocrinol. 2014; 35 (1): 140–158.

34. Hazuki Komuro, Naoko Sato, Ayaka Sasaki, Naoki Suzuki, Michiko Kano et all. Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. January 25, PLOS ONE 2016. doi.org/10.1371/journal.pone.0147817.

35. Sang H. R., Emeran A. M. Principles and clinical implications of the brain–gut enteric microbiota axis. Gastroenterol Hepatol. 2009; 6 (5): 14–16.

36. Bailey M. T., Coe C. L. Maternal separationdisrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 1999; 35: 146–155.

37. Macfarlane S, Dillon J. F. Microbial biofilmsin the human gastrointestinal tract. J. Appl. Microbiol. 2007; 102: 1187–1196.

38. Barbara G, et al. Interactions betweencommensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol.2005; 100: 2560–2568.

39. Dass N.B, et al. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPr43 receptor activation. Neurogastroenterol. Motil. 2007; 19: 66–74.

40. Malbert C. H. The ileocolonic sphincter. Neurogastroenterol. Motil. 2005; 17 (1): 41–49.

41. Nealson K. H., Platt T., Hastings J. W. Cellular control of the synthesis and activity of the bacterial luminescent system. J. Bacteriol. 1970; 104: 313–322.

42. Roth J., et al. Molecules of intercellular communication in vertebrates, invertebrates and microbes: do they share common origins? Prog. Brain Res. 1986; 68: 71–79.

43. Hughes D. T., Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat. Rev. Microbiol. 2008; 6: 111–120.

44. Sperandio V., Torres A. G., Nataro J. P. Bacteria-host communication: the language of hormones. Proceedings of the National Academy of Sciences USA. 2003; 100: 8951–8956.

45. Walsh J. H., Mayer E. A. Gastrointestinal peptide hormones and signal transduction. J Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 1993; 11: 18–44.

46. Курмангулов А. А., Дороднева Е. Ф., Исакова Д. Н. Функциональная активность микробиоты кишечника при метаболическом синдроме. Ожирение и метаболизм. 2016; 13 (1): 16–19.

47. Захаренко С. М., Фоминых Ю. А., Мехтиев С. Н. Микробиота кишечникачеловекаи метаболический синдром. Эффективная фармакотерапия. Гастроэнтерология. 2011; 3: 14–22.

48. Li H., Qiu T., Huang G., et al. Production of gamma-aminobutyric acid by Lactobacillus brevis NCL912 using fed-batch fermentation. Microbifl cell factories. 2010; 9: 85–86.

49. Cho Y. R., Cho J. Y., Chang H. C. Production of gamma-aminobutyric acid (GABA) by Lactobacillus buchneri isolated from kimchi and its neuroprotective effect on neuronal cells. J. Microbiol. Biotechnol. 2007; 17 (1); 104–109.

50. Luo J. et al. Ingestion of Lactobacillus strain reduces anxiety and improves cognitive function in the hyperammonemia rat. Sci. China. Life. Sci. 2014; 57 (3): 32–33.

51. Kalueff A. V., Nutt D. J. Role of GABA in anxiety and depression. Depression and Anxiety. 2007; 7: 495–517.

52. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012; 2012: 151085.

53. Aguirre M, Venema K. Does the gut microbiota contribute to obesity? Going beyond the gut feeling. Microorganisms 2015; 3: 213–35.

54. Seung-Eun Jung, Nam-SeokJoo, Kyung-Sun Han, and Kyu-Nam Kim. Obesity Is Inversely Related to Hydrogen-Producing Small Intestinal Bacterial Overgrowth in Non-Constipation Irritable Bowel Syndrome. J Korean Med Sci 2017; 32: 948–953.

55. Fan X, Sellin JH. Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther 2009; 29: 1069–77.

56. Saltzman JR, Russell RM. Nutritional consequences of intestinal bacterial overgrowth. Compr Ther 1994; 20: 523–30.

57. Park YS, Kim JS. Obesity phenotype and coronary heart disease risk as estimated by the Framingham risk score. J Korean Med Sci 2012; 27: 243–9.

58. Conterno L, Fava F, Viola R, Tuohy KM. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? Genes Nutr 2011; 6: 241–60.

59. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014; 146: 1525–33.

60. Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology1998; 45: 1643–50.

61. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (NY) 2007; 3: 112–22.

62. Basseri RJ, Basseri B, Pimentel M, Chong K, Youdim A, Low K, Hwang L, Soffer E, Chang C, Mathur R. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol (NY) 2012; 8: 22–8.

63. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil 2010; 16: 40–6.


Для цитирования:


Симаненков В.И., Тихонов С.В., Декканова В.Д. Ожирение и синдром раздраженного кишечника. Есть ли связь? Медицинский алфавит. 2019;2(13):14-19. https://doi.org/10.33667/2078-5631-2019-2-13(388)-14-19

For citation:


Simanenkov V.I., Tikhonov S.V., Dekkanova V.D. Irritable bowel syndrome in a patient with obesity: accident or regularity? Medical alphabet. 2019;2(13):14-19. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-13(388)-14-19

Просмотров: 326


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)